MeiraGTx Competitors

MeiraGTx (NASDAQ:MGTX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for MeiraGTx and Kymera Therapeutics, as reported by MarketBeat.com.

MeiraGTx presently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. Kymera Therapeutics has a consensus target price of $50.3333, suggesting a potential upside of 4.47%. Given MeiraGTx's stronger consensus rating and higher probable upside, equities analysts plainly believe MeiraGTx is more favorable than Kymera Therapeutics.

Profitability

This table compares MeiraGTx and Kymera Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares MeiraGTx and Kymera Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Kymera Therapeutics has lower revenue, but higher earnings than MeiraGTx.

Summary

MeiraGTx beats Kymera Therapeutics on 5 of the 8 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Valuation & Earnings

This table compares MeiraGTx and AlloVir's top-line revenue, earnings per share (EPS) and valuation.

AlloVir has lower revenue, but higher earnings than MeiraGTx.

Institutional & Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for MeiraGTx and AlloVir, as reported by MarketBeat.com.

MeiraGTx presently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. AlloVir has a consensus target price of $48.75, suggesting a potential upside of 59.73%. Given MeiraGTx's higher probable upside, equities analysts plainly believe MeiraGTx is more favorable than AlloVir.

Profitability

This table compares MeiraGTx and AlloVir's net margins, return on equity and return on assets.

Summary

MeiraGTx beats AlloVir on 4 of the 7 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and BioCryst Pharmaceuticals' top-line revenue, earnings per share and valuation.

MeiraGTx has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and BioCryst Pharmaceuticals, as reported by MarketBeat.com.

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. BioCryst Pharmaceuticals has a consensus target price of $11.3750, suggesting a potential upside of 2.02%. Given MeiraGTx's stronger consensus rating and higher probable upside, research analysts clearly believe MeiraGTx is more favorable than BioCryst Pharmaceuticals.

Profitability

This table compares MeiraGTx and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500.

Summary

MeiraGTx beats BioCryst Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and Vericel's top-line revenue, earnings per share and valuation.

Vericel has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 4.3% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and Vericel, as reported by MarketBeat.com.

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. Vericel has a consensus target price of $49.00, suggesting a potential upside of 15.27%. Given MeiraGTx's stronger consensus rating and higher probable upside, research analysts clearly believe MeiraGTx is more favorable than Vericel.

Profitability

This table compares MeiraGTx and Vericel's net margins, return on equity and return on assets.

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Summary

Vericel beats MeiraGTx on 9 of the 14 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and bluebird bio's top-line revenue, earnings per share and valuation.

MeiraGTx has higher earnings, but lower revenue than bluebird bio. MeiraGTx is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 3.6% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and bluebird bio, as reported by MarketBeat.com.

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. bluebird bio has a consensus target price of $68.4667, suggesting a potential upside of 138.73%. Given bluebird bio's higher probable upside, analysts clearly believe bluebird bio is more favorable than MeiraGTx.

Profitability

This table compares MeiraGTx and bluebird bio's net margins, return on equity and return on assets.

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Summary

bluebird bio beats MeiraGTx on 7 of the 13 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares MeiraGTx and Scholar Rock's top-line revenue, earnings per share and valuation.

Scholar Rock has higher revenue and earnings than MeiraGTx. Scholar Rock is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 61.9% of Scholar Rock shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by insiders. Comparatively, 24.6% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for MeiraGTx and Scholar Rock, as reported by MarketBeat.com.

MeiraGTx currently has a consensus target price of $33.00, suggesting a potential upside of 126.65%. Scholar Rock has a consensus target price of $61.60, suggesting a potential upside of 15.08%. Given MeiraGTx's higher probable upside, research analysts clearly believe MeiraGTx is more favorable than Scholar Rock.

Profitability

This table compares MeiraGTx and Scholar Rock's net margins, return on equity and return on assets.

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Summary

MeiraGTx beats Scholar Rock on 7 of the 13 factors compared between the two stocks.